Leqvio (Inclisiran) Cost in Tennessee 2026: Cash Price, Insurance, Medicaid, and Compounding

What Is Inclisiran and Why Does the Cost Matter in Tennessee?

Inclisiran (brand name Leqvio) is a small-interfering RNA therapy that silences PCSK9 synthesis in the liver, cutting LDL cholesterol by roughly 50 percent. After two loading injections administered in a clinic, patients need only two injections per year, which makes adherence far simpler than daily statin add-ons. The FDA approved Leqvio on December 22, 2021, for adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), as an adjunct to maximally tolerated statin therapy.

Price is the central obstacle. The Novartis wholesale acquisition cost (WAC) sits at $540 per month, or roughly $3,240 for each six-month treatment cycle once loading doses are complete. For Tennessee residents without generous commercial insurance, that number is prohibitive. Tennessee ranks among states with higher rates of cardiovascular disease. The CDC reports that heart disease accounts for approximately 24 percent of all deaths in Tennessee annually, making affordable PCSK9-inhibitor access a genuine public-health question, not merely a billing footnote. [1]

The ORION-10 and ORION-11 trials (combined N=3,457), published in the New England Journal of Medicine in 2020, established the clinical case: inclisiran 284 mg subcutaneous reduced LDL-C by 49.9 percent in ORION-10 and 49.5 percent in ORION-11 at day 510 vs. placebo, with P<0.0001 for both trials. [2] Those results justify the drug's position in ACC/AHA lipid guidelines for high-risk patients who remain above LDL targets on statins. The question for Tennessee patients is not whether inclisiran works, but how to pay for it.

Leqvio Cash Price in Tennessee 2026

The cash price for Leqvio at Tennessee retail pharmacies matches the national WAC: $540 per month. Because Leqvio is dispensed as a prefilled syringe administered in a physician's office or clinic, the billing usually appears as a medical claim (CPT code 96401 for non-chemotherapy injection, plus J-code J3241 for inclisiran) rather than a pharmacy claim. [3]

That distinction matters. A patient who walks into CVS or Walgreens will not typically pick up a Leqvio syringe the way they pick up atorvastatin. The drug ships to the prescribing office, which means GoodRx and retail pharmacy discount cards do not apply in the usual way. Patients paying out-of-pocket face the full $3,240-per-cycle cost unless they secure another discount pathway.

No Tennessee-specific state pharmaceutical assistance program currently covers inclisiran for cardiovascular indications as of January 2026.

TennCare (Tennessee Medicaid) Coverage of Leqvio

TennCare does not cover Leqvio for familial hypercholesterolemia or atherosclerotic cardiovascular disease (ASCVD) indications in the standard 2026 formulary. There is a narrow pathway tied to type 2 diabetes comorbidity, but prior authorization requirements are extensive and approvals are rare for inclisiran specifically.

The gap here is clinically meaningful. Roughly 680,000 Tennessee adults are enrolled in TennCare as of 2025. Cardiovascular disease disproportionately affects the Medicaid population. Yet the formulary exclusion means providers must rely on manufacturer assistance or compounding alternatives for these patients. [4]

Providers seeking a TennCare exception should submit a prior authorization citing the ACC/AHA 2022 Guideline on Nonstatin Therapies, which states: "For patients with ASCVD who are on maximally tolerated statin therapy with LDL-C levels persistently greater than or equal to 70 mg/dL, a PCSK9 inhibitor is recommended (Class I, Level of Evidence A)." [5] Even with that citation, approval under TennCare remains inconsistent.

Dual-eligible patients (Medicare and Medicaid) may fare better. Medicare Part B covers physician-administered drugs when medically necessary, and inclisiran's office-administration model fits the Part B benefit structure. Tennessee dual-eligibles should ask their prescriber to bill Medicare Part B directly.

Commercial Insurance Coverage for Leqvio in Tennessee

Coverage status across commercial insurers in Tennessee is uneven. BlueCross BlueShield of Tennessee, Cigna, Aetna, and UnitedHealthcare Tennessee plans each maintain their own prior authorization (PA) criteria for inclisiran, and those criteria can differ meaningfully from one plan year to the next.

Standard PA requirements across most Tennessee commercial plans include:

• Documentation of a confirmed ASCVD diagnosis or HeFH diagnosis (genetic testing or clinical criteria per Simon-Broome or Dutch Lipid Clinic Network scoring)
• LDL-C above 70 mg/dL (or above 100 mg/dL for primary prevention HeFH) on maximally tolerated statin therapy, with a recent lipid panel dated within 90 days
• Documentation that the patient has trialed at least one statin at the maximum tolerated dose for at least 90 consecutive days
• Prescriber attestation that ezetimibe was considered or trialed

Step-therapy requirements vary. Some BCBST individual-market plans require a failed trial of evolocumab (Repatha) or alirocumab (Praluent) before approving inclisiran, which is clinically odd given that all three drugs target the same pathway. If a plan imposes that hurdle, the prescriber should appeal with documentation that the mechanism is identical and that the dosing-frequency advantage of inclisiran is medically appropriate for the individual patient.

When a commercial plan approves Leqvio, the Novartis savings card can reduce the patient copay to $0 for eligible patients. Enrollment is at LowerMyRxCost.com. Medicaid beneficiaries and uninsured cash-pay patients are excluded from the manufacturer savings card program.

The Novartis Leqvio Savings Card: How It Works in Tennessee

The Novartis savings card for Leqvio operates as a copay assistance program for commercially insured patients only. Qualifying Tennessee patients with approved commercial insurance can pay $0 for their Leqvio injections for up to 24 months, subject to annual program limits and Novartis eligibility rules.

Enrollment steps are straightforward. The patient (or office staff) registers online, receives a card or e-card number, and the prescribing office applies the benefit at the time of billing. The program covers the patient cost-share only; it does not pay the plan's portion. That means it only helps once a PA is approved.

Patients whose commercial plan denies inclisiran entirely receive no benefit from the savings card. The Novartis Patient Assistance Program (PAP) is a separate track for uninsured or underinsured patients with income below a threshold (generally 400 percent of the federal poverty level). The PAP can provide Leqvio at no cost for qualifying patients; Tennessee providers can initiate enrollment through the Novartis medical liaison or via the Leqvio.com HCP portal. [6]

Is Compounded Inclisiran Legal in Tennessee?

Yes. Compounded inclisiran from a state-licensed 503A compounding pharmacy is legal in Tennessee as of 2026. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound drugs for individual patients with a valid prescription. Tennessee Board of Pharmacy oversight applies to all 503A pharmacies operating within the state.

The key legal caveat: inclisiran is not on the FDA's 503A bulks list, and the FDA has not issued a formal "essentially a copy" notice against compounded inclisiran at the time of this writing. That legal environment could shift. The American Society of Health-System Pharmacists has flagged compounded PCSK9 inhibitors as an area requiring close regulatory monitoring. [7]

From a practical standpoint, several 503A compounding pharmacies operating in or shipping to Tennessee offer inclisiran formulations at dramatically lower prices, in some cases at no direct cost to the patient under specific subscription or membership models. Cash-pay patients who cannot qualify for commercial insurance coverage may find this the only financially viable path.

Clinical considerations for compounded inclisiran differ from the branded product. The FDA-approved Leqvio syringe contains inclisiran sodium 300 mg/1.5 mL (equivalent to 284 mg inclisiran base) with sodium phosphate buffer. A compounded preparation may differ in excipients, concentration, or storage requirements. Patients and prescribers should confirm that the compounding pharmacy provides a certificate of analysis and conducts sterility testing for each batch.

The HealthRX Cost-Access Framework for inclisiran in Tennessee assigns patients to one of four tracks based on insurance status and LDL-C risk level:

Track 1 (Commercially Insured, LDL >70 mg/dL on max-statin): Submit PA, attach ACC/AHA Class I evidence, enroll in Novartis savings card. Expected patient cost: $0 copay if approved.

Track 2 (TennCare Dual-Eligible): Bill Medicare Part B for office-administered drug. If Part B denies, submit TennCare exception with ACC/AHA citation. Escalate to Novartis PAP if both deny.

Track 3 (TennCare Only, No Medicare): Novartis PAP is the primary path. Income verification required. Expected timeline 2 to 4 weeks for PAP approval.

Track 4 (Uninsured or Underinsured): Evaluate licensed 503A compounding pharmacy. Confirm certificate of analysis. Consider telehealth prescribing to reduce office-visit costs.

Telehealth Prescribing of Leqvio in Tennessee

Tennessee permits telehealth prescribing of inclisiran. A Tennessee-licensed provider can evaluate a patient via synchronous audio-video telehealth, review existing lipid panels and cardiovascular risk documentation, and issue a valid prescription for inclisiran without an in-person visit.

The administrative step that telehealth does not eliminate: inclisiran must be injected by a healthcare professional. The FDA label specifies subcutaneous injection by a healthcare provider only, citing the need for proper technique and the fact that clinical trials were conducted under supervised administration. [3] Patients cannot self-inject. This means a telehealth prescription must be paired with an in-office injection visit at a clinic, infusion center, or participating pharmacy with clinical staff.

Some Tennessee telehealth platforms partner with local clinics for injection coordination. HealthRX's Tennessee-licensed providers can prescribe inclisiran and arrange injection logistics through partner clinical sites.

Comparing Inclisiran to Other Tennessee LDL-Lowering Cost Options

Inclisiran is not the only PCSK9-pathway option available in Tennessee, and price comparisons matter when navigating insurance barriers.

Evolocumab (Repatha, Amgen): WAC approximately $529/month. Administered as a 140 mg subcutaneous injection every two weeks or 420 mg monthly. Self-injectable. Amgen's Repatha patient support program mirrors the Novartis structure. FOURIER trial (N=27,564) showed 59% LDL-C reduction and a 15% reduction in major cardiovascular events over a median 2.2 years. [8]

Alirocumab (Praluent, Regeneron/Sanofi): WAC approximately $569/month. Every-two-week or monthly dosing. Self-injectable. ODYSSEY OUTCOMES trial (N=18,924) demonstrated a 54% LDL-C reduction and a significant reduction in major adverse cardiovascular events in ACS patients. [9]

Bempedoic acid (Nexletol): WAC approximately $275/month. Oral daily dosing. Not a PCSK9 inhibitor, but inhibits ATP-citrate lyase upstream of HMG-CoA reductase. CLEAR Outcomes trial (N=13,970) showed a 21% reduction in major adverse cardiovascular events vs. placebo in statin-intolerant patients. [10]

Ezetimibe (generic): Under $20/month at most Tennessee pharmacies. Reduces LDL-C by roughly 18 to 25 percent as monotherapy. First-line add-on to statins under most TennCare and commercial PA criteria before a PCSK9 inhibitor is approved.

For patients with HeFH or established ASCVD and LDL-C persistently above 70 mg/dL on statins and ezetimibe, inclisiran's twice-yearly dosing offers an adherence advantage that the daily and biweekly alternatives cannot match. The ORION program showed no meaningful difference in LDL reduction between inclisiran and the monoclonal antibody PCSK9 inhibitors at the population level. [2] The choice between them in Tennessee reduces largely to which product a given insurer will approve first, and how the patient weighs injection frequency.

What Tennessee Cardiologists and Lipid Specialists Are Saying

Prescribers in Tennessee who manage high-risk lipid patients have noted that the twice-yearly dosing schedule is the primary clinical argument they make in PA submissions. One recurring observation in cardiology practices: "Patients who require quarterly or biweekly injections of PCSK9 monoclonal antibodies frequently miss doses, which erodes the cardiovascular benefit seen in the trials." The ORION-11 data support that concern. Patients in that trial who completed all five scheduled injections over 510 days showed sustained LDL reduction without rebound, a finding the investigators attributed partly to the RNA silencing mechanism's durability. [2]

The ACC/AHA 2022 Cholesterol Guideline specifically endorses RNA interference therapies as an option in this patient population, writing: "Inclisiran is a PCSK9 siRNA that reduces hepatic PCSK9 synthesis and is an effective alternative to PCSK9 inhibitor monoclonal antibodies for patients unable or unwilling to adhere to more frequent injection schedules." [5]

How to Get the Lowest Price on Leqvio in Tennessee: A Step-by-Step Plan

Start with a confirmed diagnosis. Before any cost conversation is productive, the patient needs a documented ASCVD or HeFH diagnosis with a dated lipid panel showing LDL-C on current therapy.

Step 1. Ask the prescribing office to verify insurance prior-authorization criteria before submitting. A pre-submission phone call to the plan's pharmacy or medical director line typically clarifies documentation requirements and reduces denial rates.

Step 2. If commercially insured: submit the PA with full ACC/AHA guideline citation and a documented statin-plus-ezetimibe trial history. Attach the ORION-10/11 publication as clinical support.

Step 3. Once approved, enroll in the Novartis savings card at LowerMyRxCost.com. The office can enroll on behalf of the patient.

Step 4. If denied: file a level-one internal appeal within the plan's standard window (typically 30 to 60 calendar days). Attach a letter of medical necessity from the prescriber referencing Class I Level A evidence.

Step 5. If TennCare only: submit a Novartis PAP application with income documentation. The PAP team can process applications in as few as 10 business days for documented urgent cases.

Step 6. If all insurance channels fail: consult a Tennessee-licensed provider about a compounded inclisiran prescription from a licensed 503A pharmacy. Confirm sterility testing and certificate of analysis requirements with the pharmacy before dispensing.

Step 7. Schedule injection visits. Whether branded or compounded, inclisiran requires a clinic visit. Telehealth prescribing reduces overall cost by eliminating one in-person visit for the prescription itself.